- PPHM has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $2.9 million.
- PPHM has traded 184,011 shares today.
- PPHM is trading at 2.08 times the normal volume for the stock at this time of day.
- PPHM is trading at a new low 3.36% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in PPHM with the Ticky from Trade-Ideas. See the FREE profile for PPHM NOW at Trade-Ideas More details on PPHM: Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Currently there are 2 analysts that rate Peregrine Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Peregrine Pharmaceuticals has been 1.3 million shares per day over the past 30 days. Peregrine has a market cap of $275.0 million and is part of the health care sector and drugs industry. The stock has a beta of 1.46 and a short float of 5.5% with 5.24 days to cover. Shares are up 5% year-to-date as of the close of trading on Friday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Peregrine Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Biotechnology industry average. The net income has significantly decreased by 33.6% when compared to the same quarter one year ago, falling from -$9.72 million to -$12.99 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, PEREGRINE PHARMACEUTICLS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has decreased to -$9.46 million or 16.23% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- The share price of PEREGRINE PHARMACEUTICLS INC has not done very well: it is down 15.61% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- PEREGRINE PHARMACEUTICLS INC's earnings per share declined by 33.3% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, PEREGRINE PHARMACEUTICLS INC continued to lose money by earning -$0.22 versus -$0.25 in the prior year. For the next year, the market is expecting a contraction of 40.9% in earnings (-$0.31 versus -$0.22).
- You can view the full Peregrine Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.